1. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn's Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2. (17th August 2016) Authors: Feagan, B; Gasink, C; Lang, Y; Friedman, JR; Johanns, J; Gao, L-L; Sands, B; Hanauer, S; Rutgeerts, P; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Tulassay, Z; Seidler, U; Sandborn, WJ Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗